Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides

Prostate

Volumn 32, Issue 4, 1997, Pages 272-278

  Tjoa, B A ^a   Erickson, S J ^a   Bowes, V A ^a   Ragde, H ^a   Kenny, G M ^a   Cobb, O E ^a   Ireton, R C ^a   Troychak, M J ^a   Boynton, A L ^a   Murphy, G P ^a  

^a NORTHWEST HOSPITAL   (United States)

Author keywords

Dendritic cells; Follow up observation; Immunotherapy; Phase I trial; Prostate cancer; T cell

Indexed keywords

ALKALINE PHOSPHATASE; MEMBRANE ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ARTICLE; AUTOTRANSPLANTATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER;

ALKALINE PHOSPHATASE; AMINO ACID SEQUENCE; BIOLOGICAL MARKERS; CELLS, CULTURED; DENDRITIC CELLS; FOLLOW-UP STUDIES; HEMATOCRIT; HUMANS; IMMUNOTHERAPY; INFUSIONS, INTRAVENOUS; LYMPHOCYTE COUNT; MALE; PEPTIDE FRAGMENTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0030758368     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19970901)32:4<272::AID-PROS7>3.0.CO;2-L     Document Type: Article

References (12)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1996. CA 1996;46:5-27.
2. Jones G, Mettlin C, Murphy G, Guinan P, Herr H, Hussey D, Chmiel J, Fremgen A, Clive R, Zuber-Ocwieja K, Winchester D: Patterns of care for carcinoma of the prostate gland: Results of a national survey of 1984 and 1990. J Am Coll Surg 1995;180:545-554.
3. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-1457.
4. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995;92:432-436.
5. Ioannides CG, Fisk B, Pollack M, Frazier ML, Wharton JT, Freedman RS: Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize common determinants on non-ovarian tumour clones. Scand J Immunol 1993;37:413-424.
6. Morton DL, Foshag LJ, Hoon DSB: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463-482.
7. Pardoll D: New strategies for active immunotherapy with genetically engineered tumor cells. Curr Opin Immunol 1992;4:619-623.
8. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A: Phase I clinical trial: T-cell therapy of prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-380.
9. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostate cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-936.
10. Murphy G, Ragde H, Kenny G, Barren R III, Erickson S, Tjoa B, Boynton A, Holmes E, Gilbauch J, Douglas T: Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res 1995;15:1473-1480.
11. Tjoa B, Erickson S, Barren R III, Ragde H, Kenny G, Boynton A, Murphy G: In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy. Prostate 1995;27:63-39.
12. Parham P, Brodsky FM: Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum Immunol 1981;3:277-299.